Dec 12025 Immorta Bio Announces Publication of International Patent Application for SenoVax™, a First-in-Class Senolytic Immunotherapy Targeting the Root Causes of Aging Demonstrates Powerful Anti-Cancer Activity Across Multiple Tumor Models MIAMI BEACH, Fla., Nov. 25, 2025
